Clovis Oncology | GenomeWeb

Clovis Oncology

Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.

Interim data showed 40 percent of patients with a DNA repair signature experienced tumor shrinkage when treated with the drug.

Originally published August 8.
NEW YORK (GenomeWeb) – Clovis Oncology this week reported that the company had incurred a net loss for the second quarter of $34.8 million, compared to $19.3 million in the second quarter of 2013.

FDA Clears Sequenom's IMPACT Dx to Aid Thrombophilia Diagnosis
The US Food and Drug Administration this week cleared Sequenom's IMPACT Dx Factor V Leiden and Factor II genotyping test.

A team led by researchers at the University of Copenhagen has completed a proteome-wide analysis of protein-polyADP-ribosylation, or PARylation, a post-translational modification thought to play a key role in DNA damage repair.

Clovis Oncology has decided to halt development of its investigational agent CO-101 as an alternative for pancreatic cancer patients who are poor responders to the standard chemotherapy agent gemcitabine after a clinical trial failed to show any improvement in survival time in a

Drug developer Clovis Oncology is planning to report data from a clinical trial later this year that may yield a new treatment option for pancreatic cancer patients who are poor responders to gemcitabine.

Pages

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.